Company Overview
Snapshot
Founded in October 2022 by Osnat Ashur-Fabian, DIO TREE operates with 1–10 employees. The company has raised $1.05 million across two funding rounds from NGT HealthCare II and Israel Innovation Authority. In January 2024, DIO TREE secured a grant from the Israel Innovation Authority.
Business overview
DIO TREE is a Health Tech & Life Sciences company focused on developing a novel small molecule for the treatment of ovarian cancer. Its core technology involves inhibiting the DIO3 enzyme, a significant driver in various cancer types, particularly ovarian cancer, through a series of small molecules. The company operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting patients and the broader biotechnology market.
Strategic signal
In August 2023, DIO TREE was featured in a Calcalistech.com article highlighting its potential to revolutionize cancer treatment with a single drug. This signals strong market interest and validation for the company's innovative approach to oncology, suggesting a promising trajectory for its therapeutic development and potential impact on patient care.
Log in to access full profile ›Company Intelligence Q&A
- What is DIO TREE's primary focus?
- DIO TREE is developing a novel small molecule for the treatment of ovarian cancer, based on inhibiting the DIO3 enzyme.
- When was DIO TREE founded?
- DIO TREE was founded in October 2022.
- Who is a founder of DIO TREE?
- Osnat Ashur-Fabian is a founder of DIO TREE, serving as CSO.
- Which investors participated in DIO TREE's December 2022 funding round?
- In December 2022, DIO TREE received funding from NGT HealthCare II and the Israel Innovation Authority.